Trial intelligence / Profile preview

Oxervate in neurotrophic keratitis (China real‑world PK/IV study)

CTR20220066Phase 4Completed

Sponsor
Dompé
Start
Jan 2022
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

A Phase 4 trial of cenegermin in neurotrophic keratitis (NK), sponsored by Dompé. Started Jan 2022; status: completed.

02

Drugs

cenegermin
03

Conditions

neurotrophic keratitis (NK)

Beyond the preview

Go deeper on CTR20220066.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20220066.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call